Mumbai, May 23 -- Profit before tax (PBT) jumped 15.6% YoY to Rs 3,254.35 crore in Q4 FY25.

During the quarter, EBITDA stood at Rs 3,716.1 crore (including other operating revenues), up 22.4% with resulting EBITDA margin of 28.7%.

India formulations sales were Rs 4,213 crore for Q4FY25, a growth of 13.6% over Q4 last year and accounted for 32.9% of total consolidated sales for the quarter.

US formulation sales were $464 million for Q4FY25, lower by 2.5% over Q4 FY24 and accounted for 31.4% of total consolidated sales for the quarter.

Formulation sales in emerging markets sales were $261 million for Q4FY25, a growth of 6.3% over Q4 last year and accounted for 17.6% of total consolidated sales for the quarter.

Formulation sales in Rest...